Clopidogrel (brand name Plavix) is an antiplatelet medicine that reduces the risk of
myocardial infarction (MI) and stroke in individuals with acute coronary syndrome (ACS) …

Abbreviation of the duration of dual antiplatelet therapy (DAPT)(one or three months) has
been recently proposed, especially for high bleeding risk patients, after percutaneous …

Coronary artery disease (CAD) is the leading cause of death in both developed and
developing nations. The objective of this study was to identify risk factors for coronary artery …

Background: Comatose survivors of out-of-hospital cardiac arrest (OHCA) undergoing
percutaneous coronary intervention (PCI) and target temperature management (TTM) are at …

The elderly represent an increasing proportion of patients presenting with acute coronary
syndrome (ACS). Various data have shown that the benefits of percutaneous coronary …

Objective This research aims to investigate the impact of individualized antiplatelet therapy
guided by thromboelastography with platelet mapping (TEG-PM) on the clinical outcomes of …

Introduction: This study aimed to compare the outcomes and safety in patients aged≥ 75
years and those aged< 75 years who underwent stent-assisted endovascular treatment for …

Limited data comparing prasugrel and ticagrelor in acute coronary syndrome are available.
Online databases, including MEDLINE and Cochrane Central, were queried to compare …

Introduction: This study aimed to compare the outcomes and safety in patients aged≥ 75
years and those aged< 75 years who underwent stent-assisted endovascular treatment for …

Lääkehoito on oleellinen osa potilaan hoitoa ensihoidossa. Laskimo on yleinen
lääkkeenantoreitti ja tätä kautta lääkkeen vaikutukset ilmenevät yleensä nopeasti. Jotta …